Biohaven Ltd. stock moved higher on Thursday following the company announcement that its Phase 2 clinical trial of taldefgrobep alfa for the treatment of obesity has completed enrollment. Shares rose 2% on the news, which confirms the trial has met its target participant numbers and remains on track to produce topline results in the second half of 2026.
The study is a randomized, double-blind, placebo-controlled trial designed to evaluate taldefgrobep administered as monotherapy in adults living with overweight and obesity. Investigators are testing both once-weekly and once-monthly dosing regimens. The protocol calls for a 24-week double-blind treatment phase, followed by a 24-week open-label extension. The trial is targeting approximately 150 participants and is being run across 20 clinical sites in the United States.
Taldefgrobep targets the myostatin-activin signaling pathway and is described by the company as a novel inhibitor that acts on both fat and muscle. The trial’s primary endpoint is the percent change in total body weight from baseline to Week 24. Secondary endpoints include percent change in total body fat mass and percent change in total body lean mass.
Earlier clinical data cited by the company indicate that taldefgrobep produced reductions in fat mass while increasing lean muscle mass in healthy adults and other non-obese populations. In a Phase 1 study, participants treated with taldefgrobep experienced reductions in total body fat mass of more than 6% and increases in lean muscle mass of up to 4% after 29 days of dosing.
The company reports that taldefgrobep has now been evaluated in more than 700 clinical trial participants and that it has been well tolerated, with low rates of serious adverse events and low rates of adverse events leading to early discontinuation. Nonclinical work in obese mouse models is also referenced, where taldefgrobep, both alone and combined with a GLP-1 agonist, produced reductions in fat mass and body weight while increasing lean mass.
The completion of enrollment clears a key operational milestone for the program. With data readout timing set for the latter half of 2026, market participants will await the topline results to assess the therapy’s performance against the trial’s predefined weight and body composition endpoints.
Summary
Biohaven has finished enrolling its Phase 2 study of taldefgrobep alfa in adults with overweight and obesity. The multicenter, randomized, double-blind trial - which includes both weekly and monthly dosing arms and a 24-week double-blind period followed by a 24-week open-label extension - aims to evaluate changes in total body weight, fat mass, and lean mass. Topline results are expected in the second half of 2026.
Key points
- Biohaven reported a 2% intraday share increase after confirming full enrollment in its Phase 2 obesity trial.
- The study is a randomized, double-blind, placebo-controlled design with once-weekly and once-monthly dosing options and targets about 150 participants across 20 U.S. sites.
- The primary endpoint is percent change in total body weight at Week 24; secondary endpoints include changes in total body fat mass and lean mass - implications affect the biotech and pharmaceutical sectors and related healthcare markets.
Risks and uncertainties
- Final efficacy and safety outcomes remain unknown until topline data are released in the second half of 2026 - clinical and investor decisions should await those results.
- Prior human data cited were in healthy adults and other non-obese populations, and some supporting evidence comes from obese mouse models - the extent to which those findings translate to the enrolled overweight and obese adult population will be revealed only after trial readout.
- The trial’s target enrollment is approximately 150 participants, a defined sample size that will shape the statistical conclusions drawn from the study data.
Investors and industry observers will be monitoring the upcoming topline release to evaluate taldefgrobep’s effect on body weight and composition as defined by the trial’s endpoints. Until the data are available, the program’s clinical and commercial potential remains to be determined by the forthcoming results.